Cancer and venous thromboembolism. Clinical implications of a strong association

Pathophysiology of Haemostasis and Thrombosis

Volumn 35, Issue 1-2, 2006, Pages

  Prandoni, Paolo ^a,b  

^a UNIVERSITY OF PADOVA   (Italy)

^b UNIVERSITY OF PADUA MEDICAL SCHOOL   (Italy)

Author keywords

Cancer Anticoagulation; Deep vein thrombosis; Pulmonary embolism; Thrombophilia. heparin; Venous thromboembolism; Venous thrombosis; Warfarin

Indexed keywords

LOW MOLECULAR WEIGHT HEPARIN; WARFARIN;

CANCER; CANCER CHEMOTHERAPY; CENTRAL VENOUS CATHETER; CLINICAL TRIAL; CONFERENCE PAPER; DISEASE ASSOCIATION; HORMONAL THERAPY; HUMAN; IMMOBILIZATION; PREVALENCE; PRIORITY JOURNAL; PROGNOSIS; RISK FACTOR; SURGERY; VENOUS THROMBOEMBOLISM;

HEPARIN, LOW-MOLECULAR-WEIGHT; HUMANS; NEOPLASMS; PREMEDICATION; PROGNOSIS; THROMBOEMBOLISM; VENOUS THROMBOSIS;

EID: 33748455515     PISSN: 14248832     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (42)

1. Shen VS, Pollak EW. Fatal pulmonary embolism in cancer patients: is heparin prophylaxis justified? South Med J 1980;73:841-3.
2. Deitcher SR. Cancer-related deep venous thrombosis: clinical importance, treatment challenges, and management strategies. Semin Thromb Hemost 2003;29:247-58.
3. Blom JW, Doggen CJ, Osanto S, Rosendaal FR. Malignancies, prothrombotic mutations, and the risk of venous thrombosis. JAMA 2005;293:715-22.
4. Prandoni P, Falanga A, Piccioli A. Cancer and venous thromboembolism. Lancet Oncology 2005;6:401-10.
5. Prandoni P, Piccioli A, Girolami A. Cancer and venous thromboembolism: an overview. Haematologica 1999;84:437-45.
6. Bergqvist D, Agnelli G, Cohen AT, Eldor A, Nilsson PE, Le Moigne-Amrani A, Dietrich-Nieto F. Duration of prophylaxis against venous thromboembolism with enoxaparin after surgery for cancer. N Engl J Med 2002;346:975-80.
7. Levine MN. Prevention of thrombotic disorders in cancer patients undergoing chemotherapy. Thromb Haemost 1997;78:133-6.
8. Khorana AA, Francis CW, Culakova E, Lyman GH. Risk factors for chemotherapy-associated venous thromboembolism in a prospective observational study. Cancer 2005;104:2822-9.
9. Prichard KI, Paterson AHG, Paul NA, Zee B, Fine S, Pater J. Increased thromboembolic complication with concurrent tamoxifen and chemotherapy in a randomized trial of adjuvant therapy for women with breast cancer. J Clin Oncol 1996;14:2731-7.
10. Coombes RC, Hall E, Gibson LJ, Paridaens R, Jassem J, Delozier T, Jones SE, Alvarez I, Bertelli G, Ortmann O, Coates AS, Bajetta E, Dodwell D, Coleman RE, Fallowfield LJ, Mickiewicz E, Andersen J, Lonning PE, Cocconi G, Stewart A, Stuart N, Snowdon CF, Carpentieri M, Massimini G, Bliss JM. A randomized trial of exemestane after two to three years of tamoxifen therapy in postmenopausal women with primary breast cancer. N Engl J Med 2004;350:1081-92.
11. Bern MM, Lokich JJ, Wallach SR, Bothe A Jr, Benotti PN, Arkin CF, Greco FA, Huberman M, Moore C. Very low dose of warfarin can prevent thrombosis in central venous catheters. A prospective trial. Ann Intern Med 1990;112:423-8.
12. Monreal M, Alastrue A, Rull M, Mira X, Muxart J, Rosell R, Abad A. Upper extremity deep venous thrombosis in cancer patients with venous access devices- prophylaxis with a low molecular weight heparin (fragmin). Thromb Haemost 1996;75:251-3.
13. Geerts WH, Pineo GF, Heit JA, Bergqvist D, Lassen MR, Colwell CW, Ray JG. Prevention of venous thromboembolism: the seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest 2004;126:338-400S.
14. Agnelli G, Bergqvist D, Cohen AT, Gallus AS, Gent M. Randomized clinical trial of postoperative fondaparinux versus perioperative dalteparin for prevention of venous thromboembolism in high-risk abdominal surgery. Br J Surg 2005;92:1212-20.
15. Levine MN, Hirsh J, Gent M, et al. Double-blind randomized trial of very-low-dose warfarin for prevention of thromboembolism in stage IV breast cancer. Lancet 1994;343:886-9.
16. Couban S, Goodyear M, Burnell M, Dolan S, Wasi P, Barnes D, Macleod D, Burton E, Andreou P, Anderson DR. Randomized placebo-controlled study of low-dose warfarin for the prevention of central venous catheter-associated thrombosis in patients with cancer. J Clin Oncol 2005;23:4063-9.
17. Heaton DC, Han DY, Inder A. Minidose warfarin as prophylaxis for central vein catheter thrombosis. Intern Med 2002;32:84-8.
18. Karthaus M, Kretzschrnar A, Kroning H, Biakhov M, Irwin D, Marschner N, Slabber C, Fountzilas G, Garin A, Abecasis NG, Baronius W, Steger GG, Sudhoff T, Giorgetti C, Reichardt P. Dalteparin for prevention of catheter-related complications in cancer patients with central venous catheters: final results of a double-blind, placebo-controlled phase III trial. Ann Oncol 2005 (in press).
19. Büller HR, Agnelli G, Hull RD, Hyers TM, Prins MH, Raskob GE. Antithrombotic therapy for venous thromboembolic disease: the seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest 2004;126:401-28S.
20. Prandoni P, Lensing AWA, Cogo A, Cuppini S, Villalta S, Carta M, Cattelan AM, Polistena P, Bernardi E, Prins MH. The long-term clinical course of acute deep venous thrombosis. Ann Intern Med 1996;125:1-7.
21. Heit JA, Mohr DN, Silverstein MD, Petterson TM, O'Fallon WM, Melton III LJ. Predictors of recurrence after deep vein thrombosis and pulmonary embolism. A population-based cohort study. Arch Intern Med 2000;160:761-8.
22. Prandoni P, Lensing AWA, Piccioli A, Bernardi E, Simioni P, Girolami B, Marchiori A, Sabbion P, Prins MH, Noventa F, Girolami A. Recurrent venous thromboembolism and bleeding complications during anticoagulant treatment in patients with cancer and venous thrombosis. Blood 2002;100:3484-8.
23. Hutten B, Prins M, Gent M, Ginsberg J, Tijsen JGP, Buller HR. Incidence of recurrent thromboembolic and bleeding complications among patients with venous thromboembolism in relation to both malignancy and achieved international normalized ratio: a retrospective analysis. J Clin Oncol 2000;18:3078-83.
24. Palareti G, Legnani C, Lee A, Manotti C, Hirsh J, D'Angelo A, Pengo V, Moia M, Coccheri S. A comparison of the safety and efficacy of oral anticoagulation for the treatment of venous thromboembolic disease in patients with or without malignancy. Thromb Haemost 2000;84:805-10.
25. Lee AY, Levine MN, Baker RI, Bowden C, Kakkar AK, Prins M, Rickles FR, Julian JA, Haley S, Kovacs MJ, Gent M. Low-molecular-weight heparin versus a coumarin for the prevention of recurrent venous thromboembolism in patients with cancer. N Engl J Med 2003;349:146-53.
26. Meyer G, Marjanovic Z, Valcke J, Lorcerie B, Gruel Y, Solal-Celigny P, Le Maignan C, Extra JM, Cottu P, Farge D. Comparison of low-molecular-weight heparin and warfarin for the secondary prevention of venous thromboembolism in patients with cancer. Arch Intern Med 2002;162:29-35.
27. Kakkar AK, Levine MN, Kadziola Z, Lemoine NR, Low V, Patel HK, Rustin G, Thomas M, Quigley M, Williamson RC. Low molecular weight heparin, therapy with dalteparin, and survival in advanced cancer: the fragmin advanced malignancy outcome study. J Clin Oncol 2004;22:1944-8.
28. Klerk CP, Smorenburg SM, Otten HM, Lensing AW, Prins MH, Piovella F, Prandoni P, Bos MM, Richel DJ, van Tienhoven G, Buller HR. The effect of low molecular weight heparin on survival in patients with advanced malignancy. J Clin Oncol 2005;23:2130-5.
29. Altinbas M, Coskun HS, Er O, Ozkan M, Eser B, Unal A, Cetin M, Soyuer S. A randomized clinical trial of combination chemotherapy with and without low-molecular-weight heparin in small cell lung cancer. J Thromb Haemost 2004;2:1266-71.
30. Lee AY, Rickles FR, Julian JA, Gent M, Baker RI, Bowden C, Kakkar AK, Prins M, Levine MN. Randomized Comparison of Low Molecular Weight Heparin and Coumarin Derivatives on the Survival of Patients With Cancer and Venous Thromboembolism. J Clin Oncol 2005;23:2123-9.
31. Schulman S, Lindmarker P. Incidence of cancer after prophylaxis with warfarin against recurrent venous thromboembolism. N Engl J Med 2000;342:1953-8.
32. Boccaccio C, Sabatino G, Medico E, Girolami F, Follenzi A, Reato G, Sottile A, Naldini L, Comoglio PM. The MET oncogene drives a genetic programme linking cancer to haemostasis. Nature 2005;434:396-400.
33. Prandoni P, Lensing AWA, Büller HR, Cogo A, Prins MH, Cattelan AM, Cuppini S, Noventa F, ten Cate JW. Deep-vein thrombosis and the incidence of subsequent symptomatic cancer. N Engl J Med 1992;327:1128-33.
34. Bura A, Cailleux N, Bienvenu B, Leger P, Bissery A, Boccalon H, Fiessinger JN, Levesque H, Emmerich J. Incidence and prognosis of cancer associated with bilateral venous thrombosis: a prospective study of 103 patients. J Thromb Haemost 2004;2:441-4.
35. Schutgens RE, Beckers MM, Haas FJ, Biesma DH. The predictive value of D-dimer measurement for cancer in patients with deep vein thrombosis. Haematologica 2005;90:214-9.
36. Sorensen HT, Mellemkjaer L, Steffensen H, Olsen JH, Nielsen GL. The risk of a diagnosis of cancer after primary deep-venous thrombosis or pulmonary embolism. N Engl J Med 1998;338:1169-73.
37. Baron JA, Gridley G, Weiderpass E, Nyren G, Linet M. Venous thromboembolism and cancer. Lancet 1998;351:077-80.
38. Murchison JT, Wylie L, Stockton DL. Excess risk of cancer in patients with primary venous thromboembolism: a national, population-based cohort study. Br J Cancer 2004;91:92-5.
39. White RH, Chew HK, Zhou H, Parikh-Patel A, Harris D, Harvey D, Wun T. Incidence of venous thromboembolism in the year before the diagnosis of cancer in 528,693 adults. Arch Intern Med 2005;165:1782-7.
40. Sorensen HT, Pedersen L, Mellemkjaer L, Johnsen SP, Skriver MV, Olsen JH, Baron JA. The risk of a second cancer after hospitalisation for venous thromboembolism. Br J Cancer 2005;93:838-41.
41. Sorensen HT, Mellemkjaer L, Olsen JH, Baron JA. Prognosis of cancers associated with venous thromboembolism. N Engl J Med 2000;343:1846-50.
42. Piccioli A, Lensing AWA, Prins MH, Falanga A, Scannapieco GL, Ieran M, Cigolini M, Ambrosio GB, Monreal M, Girolami A, Prandoni P. Estensive screening for occult malignant disease in idiopathic venous thromboembolism. J Thromb Haemost 2004;2:884-89.